Dr Amol Akhade (@suyogcancer) 's Twitter Profile
Dr Amol Akhade

@suyogcancer

Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists

ID: 1135941148378247168

linkhttp://suyogcancerclincs.com calendar_today04-06-2019 16:07:29

6,6K Tweet

3,3K Takipçi

125 Takip Edilen

Dr Amol Akhade (@suyogcancer) 's Twitter Profile Photo
Dr Amol Akhade
@suyogcancer

24 days ago

What's new data coming up in PD-L1 negative advanced NSCLC? Volrustomig , monoclonal bispecific antibody in combination with chemotherapy for First line mNSCLC shows good ORR and DCR in phase 1b trial in both non Squamous and Squamous histology. But 7 treatment related deaths ,

What's new data coming up in PD-L1 negative advanced NSCLC? Volrustomig , monoclonal bispecific antibody in combination with chemotherapy for First line mNSCLC shows good ORR and DCR in phase 1b trial in both non Squamous and Squamous histology. But 7 treatment related deaths ,